There are 699 resources available
156P - Molecular genetic phenotypes of colorectal cancer
Presenter: Krashikhina Tatiana
Session: Poster Display session
157TiP - A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD): The CORRECT-MRD I study
Presenter: Gopalakrishnan Srinivasan
Session: Poster Display session
158TiP - Exploiting circulating tumor DNA (ctDNA) to intensify the adjuvant (adj) or post-adj treatment of stage III and high-risk stage II resected colon cancer patients (pts): The ERASE-CRC project by GONO
Presenter: Veronica Conca
Session: Poster Display session
159TiP - COPERNIC: A study of on-treatment circulating tumour (ct)DNA changes in chemo-refractory colorectal cancer (CRC) patients
Presenter: Irene Assaf
Session: Poster Display session
160TiP - A phase I/II study of CFT1946, a novel BIDAC degrader targeting mutant BRAF V600 solid tumors including metastatic colorectal cancer (CRC) in combination with cetuximab
Presenter: Maria Elena Elez Fernandez
Session: Poster Display session
161TiP - A phase II study of mFOLFOXIRI after metastasectomy in patients with oligometastatic colorectal cancer (FANTASTIC study)
Presenter: Masataka Ikeda
Session: Poster Display session
162TiP - Phase II study of consolidation treatment with holmium-166 (166Ho) TARE followed by maintenance systemic therapy (MT) in unresectable liver-limited (ULL) colorectal cancer (CRC) patients (pts) after standard first-line induction therapy: The HAITI trial
Presenter: Martina Carullo
Session: Poster Display session
163TiP - ICE study: Combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen in RAS/BRAF WT/MSS mCRC
Presenter: YINGYING HUANG
Session: Poster Display session
164TiP - Cytoreductive surgery and HIPEC using double agent (cisplatin+mitomycin-C) in patients with colorectal cancer: A prospective randomized controlled study
Presenter: Manindra Nayak
Session: Poster Display session
166P - Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unrese
Presenter: Stephen Chan
Session: Poster Display session